Depressive Disorder, Treatment-Resistant Clinical Trial
— iTBSOfficial title:
Treatment for Major Depressive Disorder With Intermittent Theta-burst Stimulation: a Three-track Approach in Affective Computing, Randomized Controlled Trial, and Meta-analysis
Verified date | April 2022 |
Source | Chang Gung Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study is to investigate the two different intermittent Theta Burst (iTBS) repetitive transcranial magnetic stimulation (rTMS), its effectiveness in alleviating depressive symptoms. All patients are randomized to two different iTBS groups.
Status | Active, not recruiting |
Enrollment | 70 |
Est. completion date | July 31, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. The diagnosis of major depressive disorder according to DSM-5 2. Total HAM-D17 score of greater than or equal to 18 and Item 3 score less than 4 at screening visit. CGI-S score less than 4. 3. Before treatment, patient have to stop antidepressant for at least 1 weeks. 4. Capable and willing to provide informed consent. Exclusion Criteria: 1. Have a concomitant major, unstable medical or neurologic illness : - Psychiatric disorder: Schizoprenia, Bipolar disorder, Obsessive Compulsive Disorder, Posttraumatic Stress Disorder, substance use disorder. - Severe brian disease: Brain tumor, encephalitis, brian injury. 2. Intracranial implant and other ferromagnetic materials close to the head. 3. History of Seizures. 4. Cardiac pacemaker. 5. Pregnancy. |
Country | Name | City | State |
---|---|---|---|
Taiwan | ChangGungMH | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 17-item Hamilton Depression Rating Scale | 17-item Hamilton Depression Rating Scale (range from 0 to 52 with higher scores indicating more depression) | Baseline, Week 1, Week 2, Week 4 | |
Primary | Change in Montgomery-Asberg Depression Rating Scale | Montgomery-Asberg Depression Rating Scale (range from 0 to 54 with higher scores indicating more depression) | Baseline, Week 1, Week 2, Week 4 | |
Primary | Change in Beck Anxiety Inventory | Beck Anxiety Inventory (range from 0 to 63 with higher scores indicating more severe anxitey) | Baseline, Week 1, Week 2, Week 4 | |
Secondary | Response rate after 2-week treatment at the end of iTBS (HDRD-17 ) | Improvement > 50 % of HDRD-17 | Baseline, Week 1, Week 2, Week 4 | |
Secondary | Response rate after 2-week treatment at the end of iTBS (MADRS) | Improvement > 50 % of MADRS | Baseline, Week 1, Week 2, Week 4 | |
Secondary | Changes in Clinical Global Index Severity | Clinical Global Index | Baseline, Week 1, Week 2, Week 4 | |
Secondary | Changes in Heart Rate Variability (HRV) band | Heart rate variability measured by Wegene 8Z11 | Baseline, Week 1, Day 3, Week 2, Week 4 | |
Secondary | Changes in EEG band | Changes in EEG band before and after brain stimulation. Subject EEG activity including EEG waveform, spectrum, spectrogram, and power in the slow (0.1-1 Hz), delta (1 to 4 Hz), theta (4 to 8 Hz), alpha (8 to 12 Hz), beta (12 to 25 Hz), and gamma (25 to 70 Hz) bands. | Baseline, Week 1, Day 3, Week 2, Week 4 | |
Secondary | Change in BDNF | Changes in BDNF values | Baseline, Week 2 | |
Secondary | Change in TSH | Change in TSH values | Baseline, Week 2 | |
Secondary | Change in T3 | Change in T3 | Baseline, Week 2 | |
Secondary | Change in T4 | Change in T4 | Baseline, Week 2 | |
Secondary | Change in cortisol | Change in cortisol | Baseline, Week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03851380 -
Improving Brain Stimulation Through Imaging
|
||
Completed |
NCT04977674 -
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
|
Early Phase 1 | |
Completed |
NCT03207282 -
Treatment Resistant Depression in America Latina
|
||
Completed |
NCT02691520 -
Epidemiology of Treatment Resistant Depression in Taiwan
|
Phase 4 | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Active, not recruiting |
NCT04159012 -
NESBID: Neuro-Stimulation of the Brain in Depression
|
N/A | |
Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
Completed |
NCT04239651 -
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02493868 -
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT04599855 -
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
|
Phase 4 | |
Completed |
NCT03283670 -
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
|
Phase 2 | |
Recruiting |
NCT03004521 -
Lithium Versus Quetiapine in Treatment Resistant Depression
|
Phase 4 | |
Recruiting |
NCT04783103 -
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
|
N/A | |
Completed |
NCT03434041 -
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
Terminated |
NCT03887624 -
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
|
Early Phase 1 | |
Completed |
NCT02577250 -
Ketamine Infusions for PTSD and Treatment-Resistant Depression
|
Phase 1 | |
Recruiting |
NCT02610712 -
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
|
Phase 4 | |
Completed |
NCT03051256 -
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
|
Phase 2 | |
Enrolling by invitation |
NCT05581797 -
Psilocybin-assisted Interpersonal Therapy for Depression
|
N/A | |
Completed |
NCT02782104 -
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
|
Phase 3 |